Table 1.
Clinico-pathological characteristics of 248 patients with PCNSL.
| Parameter | N(%) |
|---|---|
| Age | 59 (21-86) |
| ≤60 | 127 (51.2) |
| >60 | 121 (48.8) |
| Gender | |
| Male | 139 (56.0) |
| Female | 108 (43.5) |
| ECOG PS | |
| ≤1 | 131 (52.8) |
| >1 | 116 (46.8) |
| Cell of origin | |
| GCB | 36 (14.5) |
| Non-GCB | 117 (47.2) |
| Epstein-Barr virus | |
| Positive | 3 (1.5) |
| Negative | 193 (98.5) |
| B symptoms | |
| Yes | 6 (2.4) |
| No | 125 (50.4) |
| LDH | |
| ≤250 U/L | 103 (41.5) |
| >250 U/L | 117 (47.2) |
| Treatment | |
| Chemotherapy | 169 (68.1) |
| Radiotherapy | 9 (3.6) |
| CMT+RT | 33 (13.3) |
| First-line chemotherapy | |
| HD-MTX | 173 (85.6) |
| Others | 29 (14.4) |
| MSKCC | |
| Low | 54 (21.8) |
| Intermediate | 146 (58.9) |
| High | 48 (19.3) |
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; GCB, germinal center B cell; CMT, chemotherapy; RT, radiotherapy; HD-MTX, high-dose methotrexate; MSKCC, Memorial Sloan Kettering Cancer Center.